Alivus Life Sciences Ltd
Alivus Life Sciences Q3 FY26 earnings call: Revenue & Margins
Q3 FY26 earnings call: what management guided on revenue, margins and order book.
The short version
High single-digit revenue growth is expected for FY'26, with 5% price erosion factored in and 15-17% volume growth anticipated. The company expects high single-digit revenue growth for FY'26, driven by strong expansion in the non-GPL segment and ramp-up of CDMO projects.
From Alivus Life Sciences Ltd's Q3 FY26 earnings-call transcript · updated 23 Aug 2026.
Revenue & Sales Performance
- High single-digit revenue growth is expected for FY'26, with 5% price erosion factored in and 15-17% volume growth anticipated.
- From FY'28-'29, the full capacity of the Solapur plant going live is expected to drive double-digit growth.
- Mature molecules show stable volumes with 2-3% growth, while newer launches and upcoming patent expiries offer significant volume expansion opportunities.
- The CDMO business, despite smaller deal sizes (around $6 million per project), is scaling with steady contributions from current projects and potential new contracts expected in FY'27.
2 more points from Alivus Life Sciences Ltd's call on revenue
Pro opens every point from 15K+ earnings calls
Profitability & Margins
See what Alivus Life Sciences Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Capacity expansion from 1,400 KL to 2,100 KL reactor capacity planned over the next year, including brownfield expansions at Dahej and Ankleshwar, operational from Q2 FY'27, providing runway for at least two years for regulated markets.
- Solapur plant delayed by approximately three months; expected to start operations by July 2026, initially focused on ROW (Rest of World) markets with gradual shift to regulated markets expected by late FY'28.
- Solapur capacity slightly recalibrated from initially planned 600 KL to around 450-500 KL in phase 1, based on product mapping to avoid under-utilization.
- 400 KL capacity allocated specifically for backward integration to secure supply and margin protection for high-value molecules.
2 more points from Alivus Life Sciences Ltd's call on capex
Pro opens every point from 15K+ earnings calls
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Alivus Life Sciences Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
- The company currently has five ongoing CDMO projects.
- Projects 4 and 5 together have an expected peak revenue potential of around $12 million, likely reaching this by the second half of FY'27.
- The earlier three CDMO projects generate a run rate of about Rs. 140 crores annually.
- Alivus is in advanced discussions for two additional CDMO projects expected to be locked by Q1 FY'27.
2 more points from Alivus Life Sciences Ltd's call on order book
Pro opens every point from 15K+ earnings calls
Alivus Life Sciences Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest (Q4 FY26): revenue ₹689 Cr, net profit ₹163 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Alivus Life Sciences Ltd's management said in earlier quarters
- Q2 FY26 earnings call analysis →
- Q1 FY27 earnings call analysis →
- Q4 FY25 earnings call analysis →
- Q3 FY25 earnings call analysis →
- Q1 FY26 earnings call →
- Q2 FY25 earnings call →
- Q1 FY25 earnings call →
- Q4 FY24 earnings call →
- Q3 FY24 earnings call →
- Q2 FY24 earnings call →
- Q1 FY24 earnings call →
- Q4 FY23 earnings call →
Others in Pharmaceuticals & Biotechnology this season
- Natural Capsules (Q3 FY26)
Q3FY26 revenue from operations: ₹37.75 crore . Key investor presentation takeaways from Natural Capsules Ltd's Q3 FY26 investor presentation — and how it ranks
- Wanbury (Q3 FY26)
Q3FY26 Revenue from Operations: ₹162.45 Crore . Key investor presentation takeaways from Wanbury Ltd's Q3 FY26 investor presentation — and how it ranks against
- Gujarat Themis Biosyn Ltd (Q3 FY26)
43.37 crore, up 9.74% YoY from Rs. Key investor presentation takeaways from Gujarat Themis Biosyn Ltd's Q3 FY26 investor presentation — and how it ranks against
- Balaxi Pharma (Q3 FY26)
Q3 FY26 revenue: ₹72.54 crore, down marginally by 1% YoY from ₹73.29 crore in Q3 FY25 (Page 19). Key investor presentation takeaways from Balaxi Pharma's Q3 FY2
Arthneeti Pro · Annual
Alivus Life Sciences Ltd and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Alivus Life Sciences Ltd Q3 FY26 results?
High single-digit revenue growth is expected for FY'26, with 5% price erosion factored in and 15-17% volume growth anticipated. The company expects high single-digit revenue growth for FY'26, driven by strong expansion in the non-GPL segment and ramp-up of CDMO projects.
What is Alivus Life Sciences Ltd share price analysis?
Alivus Life Sciences Ltd currently shows a neutral. The stock trades at a P/E of 26.3 with a market cap of ₹16,341 Cr. Investors should review the full earnings analysis for detailed insights.
Is Alivus Life Sciences Ltd planning capital expenditure?
Capacity expansion from 1,400 KL to 2,100 KL reactor capacity planned over the next year, including brownfield expansions at Dahej and Ankleshwar, operational from Q2 FY'27, providing runway for at least two years for regulated markets.
Keep Alivus Life Sciences Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.